The role of ACEIs/ARBs in COVID-19: Friend or foe?
作者信息
Zhou Zhe, Qiu Yumin, Tao Jun
机构信息
Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
出版信息
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
Abstract
摘要
相似文献
1
The role of ACEIs/ARBs in COVID-19: Friend or foe?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂在2019冠状病毒病中的作用：是友还是敌？
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
2
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.2019冠状病毒病与心血管疾病：我们已知的、我们自认为已知的以及我们需要了解的情况。
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
3
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.血管紧张素转换酶2（ACE2）受体及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）与新型冠状病毒肺炎（COVID-19）疾病严重程度的关联
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
4
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
5
Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence.在 COVID-19 中使用 ACE 抑制剂和 ARB 的风险：评估证据。
Clin Pharmacol Ther. 2020 Aug;108(2):236-241. doi: 10.1002/cpt.1863. Epub 2020 May 10.
6
SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对血管紧张素转换酶2（ACE2）的下调作用以及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）的多效性作用
Hypertens Res. 2020 Sep;43(9):985-986. doi: 10.1038/s41440-020-0488-z. Epub 2020 Jun 10.
7
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
8
Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.新型冠状病毒感染中血管紧张素II的抑制作用：一种治疗方法。
Nefrologia (Engl Ed). 2020 May-Jun;40(3):213-216. doi: 10.1016/j.nefro.2020.04.006. Epub 2020 Apr 30.
9
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
10
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.停止使用 ACEI 和 ARB 类药物对 COVID-19 患者的潜在有害影响。
Elife. 2020 Apr 6;9:e57278. doi: 10.7554/eLife.57278.
引用本文的文献
1
The Influence of Viral Infections on Iron Homeostasis and the Potential for Lactoferrin as a Therapeutic in the Age of the SARS-CoV-2 Pandemic.病毒感染对铁稳态的影响，以及乳铁蛋白在 SARS-CoV-2 大流行时代作为治疗手段的潜力。
Nutrients. 2022 Jul 27;14(15):3090. doi: 10.3390/nu14153090.
本文引用的文献
1
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
2
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
3
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.2019 年新型冠状病毒刺突蛋白在预融合构象的冷冻电镜结构
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
4
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.血管紧张素转换酶抑制和血管紧张素II受体阻滞剂对心脏血管紧张素转换酶2的影响。
Circulation. 2005 May 24;111(20):2605-10. doi: 10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
Zotero 插件